Back to Journals » Lung Cancer: Targets and Therapy » Volume 10

Time To Response In Patients With Advanced Anaplastic Lymphoma Kinase (ALK)-Positive Non-Small-Cell Lung Cancer (NSCLC) Receiving Alectinib In The Phase II NP28673 And NP28761 Studies

Total article views   HTML views PDF downloads Totals
7,248 Dovepress* 6,272+ 942 7,214
PubMed Central* 976 192 1,168
Totals 7,248 1,134 8,382
*Since 13 November 2019
Total mentioned Facebook Delicious Reddit Twitter Others
2 0 0 1 0 1

View citations on PubMed Central and Google Scholar